ABVC BIOPHARMA, INC.
About ABVC BIOPHARMA, INC.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company developing drugs and medical devices to address unmet medical needs in the United States. Its pipeline includes candidates such as ABV-1501 for triple negative breast cancer, ABV-1504 for depressive disorders, ABV-1505 for ADHD, ABV-1703 for metastatic pancreatic cancer, and BLI-1301 for myelodysplastic syndromes, with several in Phase II trials. The company maintains co-development and collaboration agreements with partners including Rgene Corporation, BioHopeKing Corporation, and BioFirst Corporation, while focusing on licensing, subsidiary development, and manufacturing through BioKey. It is headquartered in Fremont, California, and trades publicly on NASDAQ under ABVC.
- 🔗 ABVC BIOPHARMA, INC.
- 🔗 ABVC BioPharma raises $3.39M in convertible notes | ABVC 8-K Filing
- 🔗 ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS and Oncology
- 🔗 Press Release
- 🔗 ABVC BioPharma, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Investors
Key highlights
- Closed $3.39M private placement of convertible notes for working capital and pipeline advancement.
- Pipeline features multiple Phase II assets targeting CNS disorders and oncology indications.
- Maintains licensing and co-development partnerships with Rgene, BioHopeKing, and BioFirst.
- Reported Q3 licensing revenue of $1.27 million alongside ongoing clinical progress.
- Total funding reached $4.92M across post-IPO equity rounds and the recent placement.
Ask StreetZero about ABVC BIOPHARMA, INC.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account